Ascendis Pharma A/S (NASDAQ:ASND) has received a consensus recommendation of “Buy” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $52.67.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Wedbush reiterated an “outperform” rating and issued a $62.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 6th. BidaskClub upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $60.00 price target on shares of Ascendis Pharma A/S in a research note on Wednesday, January 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Friday, January 19th.
A number of large investors have recently modified their holdings of ASND. BlackRock Inc. purchased a new position in Ascendis Pharma A/S in the 4th quarter worth about $17,279,000. VHCP Management II LLC raised its position in Ascendis Pharma A/S by 31.7% in the 3rd quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock worth $47,091,000 after buying an additional 312,560 shares during the last quarter. JPMorgan Chase & Co. purchased a new position in Ascendis Pharma A/S in the 3rd quarter worth about $7,163,000. Ascend Capital LLC purchased a new position in Ascendis Pharma A/S in the 4th quarter worth about $4,992,000. Finally, Allianz Asset Management GmbH purchased a new position in Ascendis Pharma A/S in the 3rd quarter worth about $4,366,000. 83.90% of the stock is owned by institutional investors and hedge funds.
Shares of Ascendis Pharma A/S (ASND) traded up $1.28 during trading on Wednesday, reaching $67.23. 210,165 shares of the company were exchanged, compared to its average volume of 230,061. The company has a market cap of $2,817.39, a PE ratio of -18.47 and a beta of 0.68. Ascendis Pharma A/S has a 52 week low of $21.95 and a 52 week high of $69.00.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.